Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H26N6O3 |
Molecular Weight | 470.523 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C2=CC=C(NC3=NC4=C(OC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2
InChI
InChIKey=LZMJNVRJMFMYQS-UHFFFAOYSA-N
InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
Molecular Formula | C26H26N6O3 |
Molecular Weight | 470.523 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.5 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
POSELTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
56.5 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
POSELTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
186 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
POSELTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
358 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
POSELTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
65.8 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
POSELTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
201 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33323529/ |
30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
POSELTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
84.8 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
POSELTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
276 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
POSELTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1040 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
POSELTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2100 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
POSELTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
368 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
POSELTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1347 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33323529/ |
30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
POSELTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33323529/ |
30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
POSELTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:09:21 GMT 2025
by
admin
on
Mon Mar 31 23:09:21 GMT 2025
|
Record UNII |
D01E4B1U35
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C124801
Created by
admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1353552-97-2
Created by
admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
|
PRIMARY | |||
|
DTXSID501112972
Created by
admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
|
PRIMARY | |||
|
10235
Created by
admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
|
PRIMARY | |||
|
Poseltinib
Created by
admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
|
PRIMARY | |||
|
C141273
Created by
admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
|
PRIMARY | |||
|
100000174648
Created by
admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
|
PRIMARY | |||
|
56644522
Created by
admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
|
PRIMARY | |||
|
D01E4B1U35
Created by
admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IRREVERSIBLE INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
IRREVERSIBLE INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
OFF-TARGET->INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |